HOME > COMMENTARY
COMMENTARY
- Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics (2)
November 2, 2009
- Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics (1)
November 2, 2009
- How Not to License a Drug into Japan
October 12, 2009
- TOPICS/Abbott Named One of the "Best Places to Launch a Career" by BusinessWeek
October 5, 2009
- NHI Drug Pricing System Reform Becomes Further Unpredictable Following Gov't Change
October 5, 2009
- COMMENTARY/Pharma Industry Watches New DPJ Administration with Both Anticipation and Concerns
September 21, 2009
- COMMENTARY/Will It Be Possible to Eliminate Use of Multiple Antipsychotics in Massive Doses?
September 14, 2009
- COMMENTARY/Establish Solid Criteria for Switching Ethical Drugs to OTC Status
September 14, 2009
- COMMENTARY/Korosho to Embark on Japanese Version of Sentinel Initiative
September 7, 2009
- COMMENTARY/Wholesalers Need to Analyze Causes of Their Failure
August 24, 2009
- COMMENTARY/Hisamitsu Aims at Growth by Fusing Its and Noven's Technologies
August 24, 2009
- COMMENTARY/Permitting MSs to Take MR Cert. Exam Offers New Business Opportunity to Wholesalers
August 3, 2009
- COMMENTARY/Fair Profits Are Essential to Spread Regenerative Medicine
August 3, 2009
- Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(1)
July 20, 2009
- Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(2)
July 20, 2009
- COMMENTARY/Global Pharmas Enhance Their Presence in Japan
July 13, 2009
- COMMENTARY/Additional Price Cuts for Long-listed Original Drugs
June 29, 2009
- COMMENTARY/Clinical Applications of ADCs Coming Closer to Reality
June 29, 2009
- SURVEY/RLS Takes Almost Four Years before Being Diagnosed
June 22, 2009
- COMMENTARY/JSHP to Promote Use of Generics
June 8, 2009
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…